The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

被引:85
作者
Nyholm, B
Orskov, L
Hove, KY
Gravholt, CH
Moller, N
Alberti, KGMM
Moyses, C
Kolterman, O
Schmitz, O
机构
[1] Aarhus Univ Hosp, Kommunehosp, Dept Med Endocrinol & Diabet M, Aarhus, Denmark
[2] Univ Aarhus, Inst Expt Clin Res, Aarhus, Denmark
[3] Newcastle Univ, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[4] Amylin Pharmaceut, Oxford, England
[5] Amylin Pharmaceut, San Diego, CA USA
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1999年 / 48卷 / 07期
关键词
D O I
10.1016/S0026-0495(99)90232-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study. Pramlintide (30 mu g four times daily) or placebo were administered for 4 weeks, after which a daytime blood profile (8:30 AM to 4:30 PM) was performed. Serum fructosamine was decreased after pramlintide (314 +/- 14 mu mol/L) compared with placebo (350 +/- 14 mu mol/L, P =.008). On the profile day, the mean plasma glucose (8.3 +/- 0.7 v 10.2 +/- 0.8 mmol/L, P =.04) and postprandial concentrations (incremental areas under the curve [AUCs] from 0 to 120 minutes) were significantly decreased during pramlintide administration (P <.01 for both) despite comparable circulating insulin levels (359 +/- 41 v 340 +/- 35 pmol/L). Mean blood glycerol values were reduced (0.029 +/- 0.004 v 0.040 +/- 0.004 mmol/L, P =.01) and blood alanine levels were elevated (0.274 +/- 0.012 v 0.246 +/- 0.008 mmol/L, P =.03) after pramlintide versus placebo. Blood lactate concentrations did not differ during the two regimens. During pramlintide administration, the AUC (0 to 120 minutes) for plasma glucagon after breakfast was diminished (P =.02), and a similar trend was observed following lunch. In addition, peak plasma glucagon concentrations 60 minutes after breakfast (45.8 +/- 7.3 v 72.4 +/- 8.0 ng/L, P =.005) and lunch (47.6 +/- 9.0 v 60.9 +/- 8.2 ng/L, P =.02) were both decreased following pramlintide. These data indicate that pramlintide (30 mu g four times daily) is capable of improving metabolic control in type 1 diabetics. This may relate, in part, to suppression of glucagon concentrations. Longer-term studies are required to ascertain whether these findings are sustained over time. Copyright (C) 1999 by W.B. Saunders Company.
引用
收藏
页码:935 / 941
页数:7
相关论文
共 42 条
[21]   GLUCAGON AND ITS FAMILY REVISITED [J].
LEFEBVRE, PJ .
DIABETES CARE, 1995, 18 (05) :715-730
[22]   ISLET AMYLOID POLYPEPTIDE RESPONSE TO GLUCOSE, INSULIN, AND SOMATOSTATIN ANALOG ADMINISTRATION [J].
MITSUKAWA, T ;
TAKEMURA, J ;
ASAI, J ;
NAKAZATO, M ;
KANGAWA, K ;
MATSUO, H ;
MATSUKURA, S .
DIABETES, 1990, 39 (05) :639-642
[23]   Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus [J].
Nyholm, B ;
Moller, N ;
Gravholt, CH ;
Orskov, L ;
Mengel, A ;
Bryan, G ;
Moyses, C ;
Alberti, KGMM ;
Schmitz, O .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (03) :1083-1089
[24]   WICK CHROMATOGRAPHY FOR RAPID AND RELIABLE IMMUNOASSAY OF INSULIN GLUCAGON AND GROWTH HORMONE [J].
ORSKOV, H ;
THOMSEN, HG ;
YDE, H .
NATURE, 1968, 219 (5150) :193-&
[25]   DECREASED HEPATIC GLUCAGON-RESPONSES IN TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
ORSKOV, L ;
ALBERTI, KGMM ;
MENGEL, A ;
MOLLER, N ;
PEDERSEN, O ;
RASMUSSEN, O ;
SEEFELDT, T ;
SCHMITZ, O .
DIABETOLOGIA, 1991, 34 (07) :521-526
[26]   ABNORMAL MEAL CARBOHYDRATE DISPOSITION IN INSULIN-DEPENDENT DIABETES - RELATIVE CONTRIBUTIONS OF ENDOGENOUS GLUCOSE-PRODUCTION AND INITIAL SPLANCHNIC UPTAKE AND EFFECT OF INTENSIVE INSULIN THERAPY [J].
PEHLING, G ;
TESSARI, P ;
GERICH, JE ;
HAYMOND, MW ;
SERVICE, FJ ;
RIZZA, RA .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (03) :985-991
[27]   PERSISTENT EFFECT OF SUSTAINED HYPERGLUCAGONEMIA ON GLUCOSE PRODUCTION IN MAN [J].
RIZZA, RA ;
GERICH, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1979, 48 (02) :352-355
[28]   IN-VITRO AUTORADIOGRAPHIC LOCALIZATION OF AMYLIN BINDING-SITES IN RAT-BRAIN [J].
SEXTON, PM ;
PAXINOS, G ;
KENNEY, MA ;
WOOKEY, PJ ;
BEAUMONT, K .
NEUROSCIENCE, 1994, 62 (02) :553-567
[29]   THE EFFECT OF INTENSIVE TREATMENT OF DIABETES ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
SHAMOON, H ;
DUFFY, H ;
FLEISCHER, N ;
ENGEL, S ;
SAENGER, P ;
STRELZYN, M ;
LITWAK, M ;
WYLIEROSETT, J ;
FARKASH, A ;
GEIGER, D ;
ENGEL, H ;
FLEISCHMAN, J ;
POMPI, D ;
GINSBERG, N ;
GLOVER, M ;
BRISMAN, M ;
WALKER, E ;
THOMASHUNIS, A ;
GONZALEZ, J ;
GENUTH, S ;
BROWN, E ;
DAHMS, W ;
PUGSLEY, P ;
MAYER, L ;
KERR, D ;
LANDAU, B ;
SINGERMAN, L ;
RICE, T ;
NOVAK, M ;
SMITHBREWER, S ;
MCCONNELL, J ;
DROTAR, D ;
WOODS, D ;
KATIRGI, B ;
LITVENE, M ;
BROWN, C ;
LUSK, M ;
CAMPBELL, R ;
LACKAYE, M ;
RICHARDSON, M ;
LEVY, B ;
CHANG, S ;
HEINHEINEMANN, M ;
BARRON, S ;
ASTOR, L ;
LEBECK, D ;
BRILLON, D ;
DIAMOND, B ;
VASILASDWOSKIN, A ;
LAURENZI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :977-986
[30]   HYPERGLUCAGONEMIA AND BLOOD-GLUCOSE REGULATION IN NORMAL, OBESE AND DIABETIC SUBJECTS [J].
SHERWIN, RS ;
FISHER, M ;
HENDLER, R ;
FELIG, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (09) :455-461